The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1229-1234.e4 , December 2009

High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations

  • Lucie Blais, PhD

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
    • Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Lucie Blais, Université de Montréal, Faculté de pharmacie, CP 6128, succursale Centre-ville, Montréal (Québec), Canada H3C 3J7.
    • ,
  • Marie-France Beauchesne, PharmD

      Affiliations

    • Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
    • Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montreal, Quebec, Canada
    • ,
  • Catherine Lemière, MD, MSc

      Affiliations

    • Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
    • ,
  • Naoual Elftouh, MSc

      Affiliations

    • Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada

Received 23 July 2009 ,Revised 16 September 2009 ,Accepted 17 September 2009.

References 

  1. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment—2004 update. J Allergy Clin Immunol. 2005;115:34–46
  2. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg Olsen J, Sorensen HT. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol. 1999;55:139–144
  3. Breton MC, Martel MJ, Vilain A, Blais L. Inhaled corticosteroids during pregnancy: a review of methodologic issues. Respir Med. 2008;102:862–875
  4. Alexander S, Dodds L, Armson BA. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol. 1998;92:435–440
  5. Bakhireva LN, Jones KL, Schatz M, Johnson D, Chambers CD. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol. 2005;116:503–509
  6. Blais L, Beauchesne MF, Rey E, Malo JL, Forget A. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax. 2007;62:320–328
  7. Dombrowski MP, Brown CL, Berry SM. Preliminary experience with triamcinolone acetonide during pregnancy. J Matern Fetal Med. 1996;5:310–313
  8. Dombrowski MP, Schatz M, Wise R, Thom EA, Landon M, Mabie W, et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. Am J Obstet Gynecol. 2004;190:737–744
  9. Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol. 1999;93:392–395
  10. Kallen BA, Otterblad OP. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17:255–261
  11. Namazy J, Schatz M, Long L, Lipkowitz M, Lillie MA, Voss M, et al. Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol. 2004;113:427–432
  12. Olesen C, Thrane N, Nielsen GL, Sorensen HT, Olsen J. A population-based prescription study of asthma drugs during pregnancy: changing the intensity of asthma therapy and perinatal outcomes. Respiration. 2001;68:256–261
  13. Perlow JH, Montgomery D, Morgan MA, Towers CV, Porto M. Severity of asthma and perinatal outcome. Am J Obstet Gynecol. 1992;167(4 pt 1):963–967
  14. Schatz M, Zeiger RS, Harden K, Hoffman CC, Chilingar L, Petitti D. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol. 1997;100:301–306
  15. Schatz M, Dombrowski MP, Wise R, Momirova V, Landon M, Mabie W, et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol. 2004;113:1040–1045
  16. Silverman M, Sheffer A, Diaz PV, Lindmark B, Radner F, Broddene M, et al. Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide. Ann Allergy Asthma Immunol. 2005;95:566–570
  17. Kallen B, Otterblad OP. Use of anti-asthmatic drugs during pregnancy, 3: congenital malformations in the infants. Eur J Clin Pharmacol. 2007;63:383–388
  18. Éricson A, Kallen B. Use of drugs during pregnancy—unique Swedish registration method that can be improved. Information from the Swedish Medical Products Agency, editor. 1–8. 1999.
  19. Régie de l'assurance maladie du Québec. Statistiques annuelles. 1-1-2006. Available at: http://www.ramq.gouv.qc.ca. Accessed October 2009.
  20. Blais L, Beauchesne MF. Use of inhaled corticosteroids following discharge from an emergency department for an acute exacerbation of asthma. Thorax. 2004;59:943–947
  21. Marceau C, Lemiere C, Berbiche D, Perreault S, Blais L. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol. 2006;118:574–581
  22. Martel MJ, Rey E, Beauchesne MF, Perreault S, Lefebvre G, Forget A, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ. 2005;330:230
  23. Martel MJ, Rey E, Beauchesne MF, Perreault S, Forget A, Maghni K, et al. Use of short-acting beta2-agonists during pregnancy and the risk of pregnancy-induced hypertension. J Allergy Clin Immunol. 2007;119:576–582
  24. Blais L, Lemiere C, Menzies D, Berbiche D. Validity of asthma diagnoses recorded in the Medical Services database of Quebec. Pharmacoepidemiol Drug Saf. 2006;15:245–252
  25. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48:999–1009
  26. Vilain A, Otis S, Forget A, Blais L. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Saf. 2008;17:345–353
  27. Heinonen O, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton: Publishing Sciences Group, Inc; 1977;
  28. Lemiere C, Bai T, Balter M, Bayliff C, Becker A, Boulet LP, et al. Adult Asthma Consensus Guidelines Update 2003. Can Respir J. 2004;11(suppl A):9A–18A
  29. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128–1137
  30. Firoozi F, Lemiere C, Beauchesne MF, Forget A, Blais L. Development and validation of database indexes of asthma severity and control. Thorax. 2007;62:581–587
  31. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049–1060
  32. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989;79:340–349
  33. National Institute of Health. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute (NHLBI); US Department of Health and Human Services; 2007;NIH publication number 08-5846
  34. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet. 1999;86:242–244
  35. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385–392
  36. Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998;58:2–5
  37. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–844
  38. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368:744–753
  39. Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. J Allergy Clin Immunol. 2008;121:1379–1384
  40. Braems G. Fetal hypoxemia on a molecular level: adaptive changes in the hypothalamic-pituitary-adrenal (HPA) axis and the lungs. Eur J Obstet Gynecol Reprod Biol. 2003;110(suppl 1):S63–S69
  41. Cousins L. Fetal oxygenation, assessment of fetal well-being, and obstetric management of the pregnant patient with asthma. J Allergy Clin Immunol. 1999;103(2 pt 2):S343–S349
  42. Guy ES, Kirumaki A, Hanania NA. Acute asthma in pregnancy. Crit Care Clin. 2004;20:731–745x
  43. Danielsson BR, Skold AC, Johansson A, Dillner B, Blomgren B. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol. 2003;193:168–176

 L.B. and C.L. are the recipients of a Salary Award from the Fonds de la recherche en santé du Québec (FRSQ).This study was funded through grants received from the FRSQ, the Canadian Institutes of Health Research, and the Canadian Foundation for Innovation. The research was completely independent from the funders.

 Disclosure of potential conflict of interest: L. Blais receives research support from AstraZeneca and Amgen. M.-F. Beauchesne receives honoraria for CE programs from AstraZeneca, GSK Canada, and BI/Pfizer Canada. C. Lemière receives research support from NIOSH and GlaxoSmithKline. The other author declares that she has no conflict of interest.

PII: S0091-6749(09)01414-6

doi: 10.1016/j.jaci.2009.09.025

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1229-1234.e4 , December 2009

Article Tools